Result of Retail Offer

This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of CRISM Therapeutics Corporation or other evaluation of any securities of CRISM Therapeutics Corporation or any other entity and should not be considered as a recommendation that any investor should subscribe for or purchase any such securities.

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Result of Retail Offer

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that the Retail Offer which launched on 26 May 2026 has successfully completed and closed today at 11:00 a.m.

The Retail Offer was significantly oversubscribed and in the light of the oversubscription, the Directors have elected to exercise their right to increase the size of the Retail Offer to £245,000 through the issue of 2,450,000 Ordinary Shares, subject to approval by Shareholders of the Resolutions at the Company's General Meeting to be held on 15 June 2026.

The proceeds of the Retail Offer, together with the Placing announced on 26 May 2026, will provide the Company with the finance required to help secure significant grant funding, subject to confirmation, progress its Phase 2 open-label clinical trial of irinotecan-ChemoSeed for the treatment of glioblastoma, and support the continued development of docetaxel-ChemoSeed for prostate cancer.

Completion of the Retail Offer and issue of the Retail Offer Shares is conditional, inter alia, upon approval of the Shareholders at the General Meeting to be held on 15 June 2026.

Capitalised terms not defined shall have the same meaning as given to them in the Circular, posted to Shareholders on 27 May 2026.

The Company's LEI is 213800XFW6MKVCHHPW88.